SBILIFE Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹21,290 Cr
verification pending
Revenue YoY
20%
reported change
EBITDA
Pending
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
SBI Life delivered a strong Q1 FY27 with New Business Premium of Rs 8,910 crore (+23% YoY) and Individual Rated Premium of Rs 3,970 crore (+14% YoY), maintaining leadership with 22.2% private market share in IRP. PAT grew 22% to Rs 720 crore driven by favorable product mix shift toward protection and non-participating savings products. VNB grew 29% to Rs 1,410 crore with margins at 26.2% (within 26-28% guidance), though temporarily impacted by elevated GTI group business contribution (37% vs typical 10-12%). Management indicated margins have bottomed and will trend toward upper end of guidance as product mix normalizes. Agency channel showed strong momentum with 20% growth, adding 34,000 agents. Key risks include GST drag continuing for 2.5 more months, elevated stamp duty impacting other expenses, and competitive pressure on individual protection growth despite 41% pure protection growth. Guidance maintained at 14-15% IRP growth and 26-28% VNB margin for FY27.
Colored figures show movement against the previous available record.
Guidance to track
- Individual rated premium growth guidance maintained at 14-15% for full year, consistent with 14% growth delivered in Q1. 3-year CAGR of 14% outpacing industry CAGR of 13%.
- Margin guidance of 26-28% maintained. Q1 at lower end due to elevated GTI contribution; management expects margins to move toward upper end as product mix normalizes in remaining quarters.
- Agency 20% YoY growth expected to continue in remaining three quarters. Added 34,000 agents (gross) and 11 new branches in Q1. Agent productivity at Rs 2 lakh. Agency 2.0 and Agency Next programs driving growth.
- Non-ULIP contribution on IRP basis targeted at 38-40% for the year, up from 35% in Q1 FY26. ULIP contribution reduced from 65% to 62% as non-par and protection segments expand.
Risks flagged
- GST drag of ~110-120bps expected to continue for next 2.5 months (until mid-September) on prorated basis. Stamp duty increase also contributing to elevated other expenses corresponding to higher sums assured being written.
- Individual protection AP growth at ~18% appears softer vs competitors reporting stronger numbers. Management attributes this to strategic shift toward lower-ticket pure term products (41% growth) from ROP (return of premium) products, resulting in lower absolute APE while improving product quality.
- 61st month persistency showing decline as COVID-era cohort (policies sold during COVID period) moves through persistency buckets. Management expects this cohort to exit by Q3 FY27, with persistency normalizing thereafter.
- Analyst raised concern about differing street views on regulatory landscape for non-par products. Management remained vague, stating only that regulations will be 'for betterment' and they are 'waiting and watching' on upcoming regulatory changes.
Key quotes
- We are sure that this lumpy kind of business doesn't happen very frequently and our growth projections for the year on AP basis remains at 14-15% and on the margin front we have definitely seen the bottom in the first quarter itself and going forward with higher focus on individual policies the margin is going to be towards the upper range.
- Pure protection within the individual protection has actually significantly improved by 52%. So non-ROP is improving as compared to the ROP.
- The product mix improvement has resulted in higher sales of these products while ULIP continues to sell normally. This has resulted in higher contribution coming from non-par and par products and as at end of quarter on IRP basis ULIP contribution has come down to 62% and non-ULIP contributing 38%.
Research modules